KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Debt to Equity (2016 - 2020)

Historic Debt to Equity for Neogenomics (NEO) over the last 12 years, with Q1 2020 value amounting to $0.19.

  • Neogenomics' Debt to Equity fell 3469.06% to $0.19 in Q1 2020 from the same period last year, while for Mar 2020 it was $0.19, marking a year-over-year decrease of 3469.06%. This contributed to the annual value of $0.19 for FY2019, which is 3613.74% down from last year.
  • Latest data reveals that Neogenomics reported Debt to Equity of $0.19 as of Q1 2020, which was down 3469.06% from $0.19 recorded in Q4 2019.
  • Over the past 5 years, Neogenomics' Debt to Equity peaked at $0.6 during Q2 2018, and registered a low of $0.19 during Q1 2020.
  • Its 5-year average for Debt to Equity is $0.33, with a median of $0.3 in 2018.
  • In the last 5 years, Neogenomics' Debt to Equity skyrocketed by 8058.87% in 2017 and then plummeted by 6607.57% in 2019.
  • Neogenomics' Debt to Equity (Quarter) stood at $0.46 in 2016, then fell by 10.12% to $0.41 in 2017, then decreased by 26.98% to $0.3 in 2018, then plummeted by 36.14% to $0.19 in 2019, then fell by 0.8% to $0.19 in 2020.
  • Its last three reported values are $0.19 in Q1 2020, $0.19 for Q4 2019, and $0.2 during Q3 2019.